Klaus Cichutek | President
Paul Ehrlich Institute

Klaus Cichutek, President, Paul Ehrlich Institute

The Paul-Ehrlich-Institut is a research and science driven Medicines Agency (veterinary and human vaccines, human biomedicines) reporting to the German Federal Ministry of Health and providing regulatory services to the European Medicines Agency EMA, EDQM, WHO and others.
Professional career:
  1976 to 1984 1985 to 1988
1988 to 1994 1994 to 2011 1999 to 2009 2009 to today
studies of and Ph.D. in biochemistry
postdoctoral scientist at the Molecular Biology and Virus Laboratory, University of California in Berkeley, U.S.A., on fellowships of the DFG (German Research Foundation) and the Univ. of California
head, 'Molecular Biology' Research Group, Paul-Ehrlich-Institut, Langen head, Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen Vice President, Paul-Ehrlich-Institut, Langen
President, Paul-Ehrlich-Institut, Langen
Research interests: Retrovirology and gene therapy (> 150 publications).
Early research on oncogenic Harvey sarcoma virus was followed by a characterisation of the apathogenic infection of African green monkeys with SIVagm and of the development of HIV-1 virus variants from a single biological virus clone in patients. In gene therapy, he generated a variety of retro- and lentiviral vectors and vector pseudotypes and he demonstrated the feasibility of cell targeting in vitro and in vivo.
Current committee and board memberships (selection):
- European "Heads of Medicines Agencies" (HMA Management Group chair; 02/2014 to 02/2018),
- "WHO Expert Committee on Biological Standardization" (ECBS) (elected chair in 2016/17/18/19/20),
- “WHO Product Development for Vaccines Advisory Committee" (PD-VAC),
- ICMRA member (“International Coalition of Medicines Regulatory Authorities”),
- founding member of the German Center for Infection Research DZIF,
- Loewe Centre for Cell and Gene Therapy Frankfurt/Main,
- Board member of the German Working Group of Departmental Research Institutes (AG Ressortforschung), - reviewer of research proposals for the Federal Ministry of Education and Research, the German Research
Foundation DFG, Fraunhofer, Helmholtz Association and the European Commission.


Day 2: Thursday 20th May 2021 - Gene Therapy @ 12:30

Advanced Therapies: development and regulation, from an EU point of view

Live presentation and audience Q&A
last published: 10/May/21 08:45 GMT

back to speakers